Your browser doesn't support javascript.
loading
A Pilot Randomised Double-Blind Study of the Tolerability and efficacy of repetitive Transcranial Magnetic Stimulation on Persistent Post-Concussion Syndrome.
Moussavi, Zahra; Suleiman, Abdelbaset; Rutherford, Grant; Ranjbar Pouya, Omid; Dastgheib, Zeinab; Zhang, Weijia; Salter, Jennifer; Wang, Xikui; Mansouri, Behzad; Lithgow, Brian.
Affiliation
  • Moussavi Z; Biomedical Engineering, University of Manitoba, Winnipeg, Canada. Zahra.Moussavi@umanitoba.ca.
  • Suleiman A; Riverview Health Centre, Winnipeg, Canada. Zahra.Moussavi@umanitoba.ca.
  • Rutherford G; Biomedical Engineering, University of Manitoba, Winnipeg, Canada.
  • Ranjbar Pouya O; Biomedical Engineering, University of Manitoba, Winnipeg, Canada.
  • Dastgheib Z; Biomedical Engineering, University of Manitoba, Winnipeg, Canada.
  • Zhang W; Biomedical Engineering, University of Manitoba, Winnipeg, Canada.
  • Salter J; Statistics Department, University of Manitoba, Winnipeg, Canada.
  • Wang X; Riverview Health Centre, Winnipeg, Canada.
  • Mansouri B; Statistics Department, University of Manitoba, Winnipeg, Canada.
  • Lithgow B; Biomedical Engineering, University of Manitoba, Winnipeg, Canada.
Sci Rep ; 9(1): 5498, 2019 04 02.
Article in En | MEDLINE | ID: mdl-30940870
This study investigates the effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on persistent post-concussion syndrome (PCS). The study design was a randomized (coin toss), placebo controlled, and double-blind study. Thirty-seven participants with PCS were assessed for eligibility; 22 were randomised and 18 completed the study requirements. Half the participants with PCS were given an Active rTMS intervention and the other half given Sham rTMS over 3 weeks. Follow ups were at the end of treatment and at 30 and 60 days. The primary outcome measure was the Rivermead Post-Concussion Symptoms Questionnaire (RPQ3 & RPQ13). The results indicate participants with more recent injuries (<12 month), who received Active rTMS, showed significant improvements compared to those of: 1) the same subgroup who received Sham, and 2) those with a longer duration of injury (>14 months) who received Active rTMS. This improvement predominantly manifested in RPQ13 in the follow up periods 1 and 2 months after the intervention (RPQ13 change (mean ± SD): at 1 month, Active = -21.8 ± 6.6, Sham = -2.2 ± 9.8; at 2 months, Active = -21.2 ± 5.3, Sham = -5.4 ± 13.7). No improvement was found in the subgroup with longer duration injuries. The results support rTMS as a tolerable and potentially effective treatment option for individuals with a recent (<1 year) concussion.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Post-Concussion Syndrome / Transcranial Magnetic Stimulation Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Sci Rep Year: 2019 Document type: Article Affiliation country: Canada Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Post-Concussion Syndrome / Transcranial Magnetic Stimulation Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Sci Rep Year: 2019 Document type: Article Affiliation country: Canada Country of publication: United kingdom